checkAd
    PDS Biotechnology Registered (B) Aktie
    3,1440
     
    EUR
    -0,76 %
    -0,0240 EUR
    Letzter Kurs 30.04.24 Tradegate
    3,3180
     
    EUR
    905 STK
    Geldkurs 09:44:48
    3,4080
     
    EUR
    880 STK
    Briefkurs 09:44:48
    ISIN: US70465T1079 · WKN: A2PF3F · SYM: EU6 · USA

    Neueste Nachrichten

    PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune HPV in Combination with KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer
    23.04.24 · globenewswire · PDS Biotechnology Registered (B)
    PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
    27.03.24 · globenewswire · PDS Biotechnology Registered (B)
    PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
    20.03.24 · globenewswire · PDS Biotechnology Registered (B)
    PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune
    13.03.24 · globenewswire · PDS Biotechnology Registered (B)
    PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
    22.01.24 · globenewswire · PDS Biotechnology Registered (B)
    PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
    16.01.24 · globenewswire · PDS Biotechnology Registered (B)
    PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
    28.11.23 · globenewswire · PDS Biotechnology Registered (B)
    PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
    14.11.23 · globenewswire · PDS Biotechnology Registered (B)
    PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
    09.11.23 · globenewswire · PDS Biotechnology Registered (B)
    PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
    07.11.23 · globenewswire · PDS Biotechnology Registered (B)
    PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO
    23.10.23 · globenewswire · PDS Biotechnology Registered (B)
    PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer
    11.10.23 · globenewswire · PDS Biotechnology Registered (B)